Memory Disorders Research Unit, Dept. of Neurology, The Neuroscience Center, N2082 Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Expert Rev Neurother. 2001 Sep;1(1):11-9. doi: 10.1586/14737175.1.1.11.
Donepezil is the most widely used acetylcholinesterase inhibitor licensed for symptomatic treatment of mild-to-moderate Alzheimer's disease. Clinical placebo-controlled trials and open-label extension studies have consistently shown that donepezil is well tolerated and gives rise to statistically significant improvements in cognition, global function and activities of daily living for at least 12 months and to less deterioration of function possibly for more than 4 years. Furthermore, donepezil may reduce neuropsychiatric symptoms and caregiver burden. Health economic studies suggest that treatment with donepezil may reduce resource utilization. Evidence-based international management guidelines recommend that treatment with a cholinesterase inhibitor should be considered in all patients with mild-to-moderate Alzheimer's disease and based on a proper diagnostic evaluation. Treatment cannot replace continuous advice to patients and caregivers.
多奈哌齐是最广泛使用的乙酰胆碱酯酶抑制剂，被批准用于治疗轻度至中度阿尔茨海默病的症状。临床安慰剂对照试验和开放性扩展研究一致表明，多奈哌齐具有良好的耐受性，并在至少 12 个月内导致认知、总体功能和日常生活活动的统计学显著改善，并可能在 4 年以上的时间内减少功能恶化。此外，多奈哌齐可能减轻神经精神症状和照顾者负担。健康经济学研究表明，多奈哌齐治疗可能减少资源利用。基于证据的国际管理指南建议，在所有轻度至中度阿尔茨海默病患者中都应考虑使用胆碱酯酶抑制剂进行治疗，并基于适当的诊断评估。治疗不能替代对患者和照顾者的持续建议。
